Free Trial
Notice: This company has been marked as potentially delisted and may not be actively trading.
NASDAQ:NEOS

Neos Therapeutics (NEOS) Stock Price, News & Analysis

Neos Therapeutics logo

About Neos Therapeutics Stock (NASDAQ:NEOS)

Key Stats

Today's Range
$1.06
$1.18
50-Day Range
$0.77
$1.18
52-Week Range
$0.45
$1.68
Volume
15.01 million shs
Average Volume
7.44 million shs
Market Capitalization
$57.22 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Neos Therapeutics, Inc., a pharmaceutical company, develops, manufactures, and commercializes products for the treatment of attention deficit hyperactivity disorder (ADHD) using its drug delivery technology platform. Its products are extended-release (XR) medications in orally disintegrating tablets or liquid suspension dosage forms. The company manufactures and markets Adzenys XR-ODT amphetamine for the treatment of ADHD; Cotempla XR-ODT methylphenidate to treat ADHD; Adzenys ER amphetamine for the treatment of ADHD; and generic Tussionex, a hydrocodone and chlorpheniramine polistirex XR oral suspension for cough and upper respiratory symptoms of a cold. It also offers NT0502, a clinical-stage product candidate that has completed Phase I pilot pharmacokinetic trial for the treatment of neurological conditions associated with excessive salivation and drooling to reduce chronic sialorrhea in patients. The company was incorporated in 2009 and is headquartered in Grand Prairie, Texas.

Receive NEOS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Neos Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

NEOS Stock News Headlines

MCET MultiCell Technologies, Inc.
NEOS/USD - NeosCoin US Dollar
Urgent: This election is rigged
If you missed it, my emergency election broadcast is now available - but will be removed soon
Cara Therapeutics, Inc. (CARA)
Presidio Partners 2007 GP, L.P.'s Net Worth
See More Headlines

NEOS Stock Analysis - Frequently Asked Questions

Neos Therapeutics, Inc. (NASDAQ:NEOS) issued its quarterly earnings data on Monday, November, 9th. The company reported ($0.10) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.05) by $0.05. The company had revenue of $12.54 million for the quarter.

Neos Therapeutics (NEOS) raised $60 million in an initial public offering on Thursday, July 23rd 2015. The company issued 4,000,000 shares at $14.00-$16.00 per share. UBS Investment Bank, BMO Capital Markets and RBC Capital Markets acted as the underwriters for the IPO and JMP Securities was co-manager.

Based on aggregate information from My MarketBeat watchlists, some other companies that Neos Therapeutics investors own include TherapeuticsMD (TXMD), Onconova Therapeutics (ONTX), Adamis Pharmaceuticals (ADMP), Acasti Pharma (ACST), SCYNEXIS (SCYX), Corbus Pharmaceuticals (CRBP) and AVEO Pharmaceuticals (AVEO).

Company Calendar

Last Earnings
11/09/2020
Today
11/01/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Pharmaceutical Preparations
Sub-Industry
N/A
Current Symbol
NASDAQ:NEOS
Fax
N/A
Employees
213
Year Founded
N/A

Profitability

Net Income
$-16,900,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$64.65 million
Book Value
($0.12) per share

Miscellaneous

Free Float
N/A
Market Cap
$57.22 million
Optionable
Optionable
Beta
1.50
These 7 Stocks Will Be Magnificent in 2024 Cover

With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.

Get This Free Report

This page (NASDAQ:NEOS) was last updated on 11/2/2024 by MarketBeat.com Staff
From Our Partners